Research programme: stem cell therapies - Cytovis

Drug Profile

Research programme: stem cell therapies - Cytovis

Alternative Names: CytoCor; CytoRet

Latest Information Update: 02 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator International Stem Cell Corporation
  • Developer Cytovis; University of California at Irvine
  • Class Eye disorder therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Corneal disorders; Retinal disorders

Most Recent Events

  • 31 Oct 2017 International Stem Cell Corporation receives patent allowance for methods for generating HLA homozygous parthenogenetic human stem cell lines in Australia
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Corneal-disorders in USA (Intraocular, Implant)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Retinal-disorders in USA (Intraocular, Implant)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top